ERIS LIFESCIENCES LIMITED Intrinsic Value
ERIS · Healthcare · Current price ₹1,273.6
Is ERIS LIFESCIENCES LIMITED undervalued?
DocStoX estimates the fair value of ERIS LIFESCIENCES LIMITED at ₹910 per share, versus the current market price of ₹1,274. That puts the stock about -28.6% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹456), Relative P/E (₹1,449), Graham floor (₹533), Analyst target (₹1,652). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹456 (bear) to ₹910 (base) to ₹1,652 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹1,274 versus an intrinsic value of ₹910, ERIS LIFESCIENCES LIMITED currently offers -28.6% of negative margin (i.e. a premium).
More on ERIS LIFESCIENCES LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.